Financiere de Tubize SA
LSE:0D53
Relative Value
The Relative Value of one 0D53 stock under the Base Case scenario is 19.11 EUR. Compared to the current market price of 61.8 EUR, Financiere de Tubize SA is Overvalued by 69%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Valuation Multiples
Multiples Across Competitors
0D53 Competitors Multiples
Financiere de Tubize SA Competitors
Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
---|---|---|---|---|---|---|---|---|
BE |
Financiere de Tubize SA
LSE:0D53
|
4.2B EUR | 4 239.2 | 45.3 | 4 228.8 | 4 228.8 | ||
JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | 4 211 733 | -5 347 888.9 | -5 459 134.4 | -5 046 864.6 | |
US |
Eli Lilly and Co
NYSE:LLY
|
696.4B USD | 20.4 | 132.9 | 60.1 | 68.9 | ||
DK |
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 17 | 47.2 | 34.6 | 37.7 | ||
UK |
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 578.3 | -15 783.5 | 3 846.3 | 17 702.3 | ||
JP |
Taisho Pharmaceutical Holdings Co Ltd
TSE:4581
|
82T JPY | 255.8 | 9 733.7 | 1 771.8 | 4 320.3 | ||
US |
Johnson & Johnson
NYSE:JNJ
|
351.8B USD | 4.3 | 8.7 | 11.6 | 15.3 | ||
US |
Merck & Co Inc
NYSE:MRK
|
332.2B USD | 5.5 | 910 | 45.2 | 88.2 | ||
UK |
AstraZeneca PLC
LSE:AZN
|
185.8B GBP | 5.1 | 39 | 140.5 | 225.4 | ||
CH |
Novartis AG
SIX:NOVN
|
182.9B CHF | 4.3 | 13.5 | 9.9 | 16.3 | ||
CH |
Roche Holding AG
SIX:ROG
|
176.2B CHF | 3 | 15.3 | 8.5 | 10 |